Article

Linking <i>Gba1</i> E326K mutation to microglia activation and mild age-dependent dopaminergic Neurodegeneration

2023-09-14

Abstract excerpt

Mutations in the GBA1 gene have been identified as a prevalent genetic risk factor for Parkinson’s disease (PD). GBA1 mutations impair enzymatic activity, leading to lysosomal dysfunction and elevated levels of α-synuclein (α-syn). While most research has primarily focused on GBA1’s role in promoting synucleinopathy, emerging evidence suggests that neuroinflammation may be a key pathogenic alteration caused by G...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8efa22c9-3faf-5505-a521-edaf550cff4a
DOI: 10.1101/2023.09.14.557673

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Linking <i>Gba1</i> E326K mutation to microglia activation and mild age-dependent dopaminergic NeurodegenerationDOI 10.1101/2023.09.14.557673Read

Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegenerationSemantic proximity Read

<i>GBA1</i> deficiency differentially affects endolysosomal trafficking in neurons versus astrocytesSemantic proximity Read

GBA mutation exacerbates α-synuclein pathology with involvement of ROS and p38 MAPK signaling in Parkinson's disease.Semantic proximity Read

Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models.Semantic proximity Read

A GM1 gangliosidosis mutant mouse model exhibits activated microglia and disturbed autophagy.Semantic proximity Read

The Molecular Impact of Glucosylceramidase Beta 1 (Gba1) in Parkinson's Disease: a New Genetic State of the Art.Semantic proximity Read

Inhibition of microglial GBA hampers the microglia-mediated anti-oxidant and protective response in neuronsSemantic proximity Read

GBA Variants and Parkinson Disease: Mechanisms and Treatments.Semantic proximity Read

The interplay between Glucocerebrosidase, α-synuclein and lipids in human models of Parkinson’s diseaseSemantic proximity Read

Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.Semantic proximity Read

Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease.Semantic proximity Read

Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.Semantic proximity Read